Nutriband Company Description

Nutriband Inc. develops a portfolio of transdermal pharmaceutical products in the United States.

The company’s lead product in development is AVERSA fentanyl, an abuse deterrent fentanyl transdermal system that provides clinicians and patients with an extended-release transdermal fentanyl product for use in managing chronic pain requiring around the clock opioid therapy.

It also develops AVERSA buprenorphine and AVERSA methylphenidate, and other transdermal pharmaceutical products.

The company has commercial development and clinical supply agreement with Kindeva Drug Delivery. The company was incorporated in 2016 and is headquartered in Orlando, Florida.

Nutriband Inc.

Country	United States
Founded	2016
Industry	Pharmaceutical Preparations
CEO	Gareth Sheridan

Contact Details

Address: 121 South Orange Avenue Orlando, Nevada 32801 United States
Phone	407 377 6695
Website	nutriband.com

Stock Details

Ticker Symbol	9WV
Exchange	Frankfurt Stock Exchange
Stock Type	Common Stock
Fiscal Year	February - January
Reporting Currency	USD
SIC Code	2834

Key Executives

Name	Position
Gareth Sheridan	Chief Executive Officer
Gerald Goodman	Chief Financial Officer
Alan Smith	Chief Operating Officer